The increase in treatment options creates an urgent need for comparative effectiveness research. Randomized, controlled trials comparing several treatments are usually not feasible, so other methodological approaches are needed. Meta-analyses provide summary estimates of treatment effects by combining data from many studies. However, an important drawback is that standard metaanalyses can compare only 2 interventions at a time. A new metaanalytic technique, called network meta-analysis (or multiple treatments meta-analysis or mixed-treatment comparison), allows assessment of the relative effectiveness of several interventions, synthesizing evidence across a network of randomized trials. Despite the growing prevalence and influence of network metaanalysis in many fields of medicine, several issues need to be addressed when constructing one to avoid conclusions that are inaccurate, invalid, or not clearly justified. This article explores the scope and limitations of network meta-analysis and offers advice on dealing with heterogeneity, inconsistency, and potential sources of bias in the available evidence to increase awareness among physicians about some of the challenges in interpretation.
T
he increase in alternative medical treatment options has led to the need for comparative effectiveness research (1, 2) . Randomized, controlled trials comparing many treatment options are usually not feasible, so other methodological approaches are needed. A meta-analysis embedded in a systematic review is a useful statistical tool that provides a summary estimate of treatment effect by combining data from many studies. However, a key limitation of standard (or pairwise) meta-analyses is that they can compare only 2 interventions at a time. When several treatment options are available, a series of individual metaanalyses provides only partial information because it can only answer questions about pairs of treatments. This does not support optimal clinical decision making because each meta-analysis is only one part of the whole picture.
The need for a method to summarize evidence across many interventions has been increasingly recognized (3) . Network meta-analysis (or multiple treatments metaanalysis or mixed-treatment comparison) has been developed to assess the relative effectiveness of several interventions and synthesize evidence across a network of randomized trials (4 -6) . The method is based on the simultaneous analysis of direct evidence (which comes from studies directly randomizing treatments of interest) and indirect evidence (which comes from studies comparing treatments of interest with a common comparator) (7) .
Several applications and methodological articles have outlined the benefits of network analysis (1, 8, 9) , which has become increasingly popular (Appendix Figure 1 , available at www.annals.org). Although most of the assumptions underlying network meta-analysis are shared with those for pairwise meta-analysis, it is far from being fully accepted and has been criticized (10) .
This article elucidates the main characteristics of network meta-analysis, focuses on questions about its main conceptual and technical challenges, and offers advice on how they might be addressed in practice. Definitions of the statistical terms used are provided in Appendix Table 1 (available at www.annals.org).
WHAT IS A NETWORK META-ANALYSIS?
Figure 1 presents a network of pharmacologic treatments for acute mania. The primary outcome for shortterm treatment efficacy is the change score on a rating scale for manic symptoms (11) . The lines between treatment nodes indicate which comparisons have been made in randomized trials. If there is no line between 2 nodes, then no studies (that is, no direct evidence) compare the 2 drugs. A network meta-analysis is a simultaneous analysis of the data from all of these randomized trials. With a network metaanalysis, the relative effectiveness of 2 treatments can be estimated even if no studies directly compare them. For example, no single study has compared aripiprazole and risperidone but using a common comparator (placebo) allows for an indirect comparison between them. Denoting aripiprazole, risperidone, and placebo as treatments A, B, and C, respectively, an indirect comparison (AB) can be obtained by subtracting the meta-analytic estimates of all studies of risperidone versus placebo (BC) from the estimate of all studies of aripiprazole versus placebo (AC):
AB indirect meta-analysis ϭ AC direct meta-analysis Ϫ BC direct meta-analysis.
If direct evidence is available (such as haloperidol vs. risperidone in Figure 1) , the network meta-analysis combines direct and indirect estimates and calculates a mixed effect size as the weighted average of the direct evidence (studies comparing haloperidol and risperidone directly) and the indirect evidence (for example, studies comparing haloperidol and risperidone via placebo). The network formed by studies of haloperidol versus risperidone, haloperidol versus placebo, and risperidone versus placebo is often called a loop of evidence. In more complex networks (with Ն4 competing treatments), indirect estimates can be derived through several loops with many different intermediate comparators (Figure 2) . The use of indirect estimates can provide information on comparisons for which no trials exist. It can also improve the precision of the direct estimate by reducing the width of the CIs compared with the direct evidence alone (8) .
IS INDIRECT EVIDENCE RANDOMIZED OR OBSERVATIONAL EVIDENCE?
Current hierarchies of evidence tend to place indirect and mixed comparisons below direct evidence because indirect comparisons may have biases similar to those in observational studies. For example, the Canadian Agency for Drugs and Technologies in Health allows indirect and mixed comparisons only as a sensitivity or supportive analysis to supplement the direct evidence (12) .
Indirect comparisons can be viewed as a special case of subgroup meta-analysis; the studies form 2 groups of comparison pairs (that is, AC and BC), and the difference between the 2 subgroup summary estimates is the indirect estimate of A versus B (Figure 1 ). An indirect estimate is calculated using estimates from direct meta-analyses, so the within-trial randomization is preserved. This process is often called adjusted indirect comparison (8) ; thus, network meta-analyses are based on randomized comparisons. Nevertheless, indirect comparison and consequently network meta-analysis provide observational evidence in that the treatments being compared have not been randomized directly within the individual trials. Standard meta-analysis has been described as providing evidence of an observational nature (13) because competing treatments have been randomized within but not across trials.
WHEN ARE INDIRECT AND MIXED COMPARISONS VALID?
The main assumption underpinning the validity of indirect and mixed comparison is that there are no important differences between the trials making different comparisons other than the treatments being compared. This assumption has been described alongside several terms in the literature, including similarity (14, 15) , transitivity (16, 17) , consistency (4), and coherence (18) . We will discuss our interpretation of these terms and different manifestations of the main assumption, highlighting the important methodological issues and their implications for drawing clinically meaningful conclusions.
Transitivity and Similarity
The synthesis of studies making a direct comparison of 2 treatments makes sense only when the studies are sufficiently similar in important clinical and methodological characteristics (effect modifiers). These effect modifiers need not be, and usually are not, identical (leading to heterogeneity of effects across studies). A valid indirect comparison (such as AB) requires that the sets of AC and BC studies are similar in their distributions of effect modifiers (for example, severity of illness at baseline, treatment dose, sample size, and study quality). Only when this is the case can we assume that the intervention effects are transitive (that is, the previously mentioned subtraction equation holds). Transitivity can be viewed as the extension of clinical and methodological homogeneity to comparisons across groups of studies that compare treatments. In complex network structures, the transitivity assumption should hold for all cases where indirect or mixed estimates are derived. Note that similarity within each comparison in the network is not sufficient to justify the transitivity assumption. Suppose that all AC studies include patients with severe illness and all BC studies include patients with moderate illness. Each study set is similar within itself (at least according to this particular characteristic), but the 2 sets deal with clinically different populations of patients. So, if severity is an effect modifier, the transitivity assumption would not hold, and synthesis of these 2 meta-analyses would not give a valid AB estimate (17) .
A special case of an effect modifier that can vary across comparisons violating the transitivity assumption is the nature of the common comparator. If comparator C is systematically different in AC and BC studies (for example, treatment C is administered as an oral tablet in AC studies but as an intramuscular injection in BC studies), then the transitivity assumption probably will not hold, and the indirect comparison between treatments A and B might not be valid.
The plausibility of the transitivity assumption requires judgment to decide whether differences in the distributions of the effect modifiers across studies are large enough to make network meta-analysis invalid. However, practical challenges are that effect modifiers are often not reported in studies and that too few studies are available per comparison to make a reasonable judgment. If an imbalanced distribution of effect modifiers is identified, adjustment can be used to improve transitivity through network meta-regression (19, 20) . Note that this use of meta-regression for adjustment is for a subtly different purpose from its traditional use to examine how treatment effects depend on study-level characteristics. Adjustment should take place only for study or patient characteristics that are effect modifiers (such as severity of illness at baseline, number of previous episodes, age, or sex) (21).
Consistency
Consistency (or coherence) is the statistical manifestation of transitivity and occurs when the subtraction equation is supported by the data. It can be evaluated only when a loop in the evidence network exists, that is, when there is direct and indirect evidence for a particular comparison of interventions. The distinction between transitivity and consistency is analogous to the distinction between clinical or methodological heterogeneity and statistical heterogeneity seen in standard meta-analysis. Heterogeneity refers to the degree of disagreement between study-specific treatment effects and is measured by differences in estimates of study treatment effect beyond what chance can explain. Inconsistency similarly refers to the degree of disagreement between source-specific (and not study-specific) treatment effects and is measured by differences between direct and indirect estimates beyond what chance can explain (16) . Heterogeneity is usually evaluated by the Cochran Q test or the I 2 statistic (22) . Consistency in a network meta-analysis can be evaluated statistically by comparing the direct and indirect summary effects in specific loops (8, 18) or across a network by fitting models that allow and do not allow for inconsistency (4, 23, 24) . A "leave-onecomparison-out" approach, often called "node splitting," can also be applied, with each direct comparison being excluded from the network and then estimating the difference between this direct evidence and the indirect evidence from the network (25) . In an empirical study of 40 published networks, inconsistency was seen in 9% of evidence loops and in 1 in 8 networks (26) . The power of tests for inconsistency is expected to be generally low (26) and might depend on the method used to estimate heterogeneity (27) .
HOW SHOULD INCONSISTENT NETWORKS BE ADDRESSED?
Despite the best efforts of investigators to construct a consistent network, statistically significant inconsistency may arise, which should be investigated when found. Systematic review protocols list potential sources of heterogeneity, possibly using them to form more homogeneous subgroups of studies and generate hypotheses for effect modifiers. Similarly, network meta-analysis should describe in the protocol a clear strategy to deal with inconsistency. Some strategies used to address heterogeneity in standard meta-analysis can be adapted and employed in network meta-analysis to tackle inconsistency, which is described in the Table. Representing all triangular closed loops in a network, a graph of the differences between direct and indirect estimates can show which loops have statistically significant inconsistency. This graph is shown for the main efficacy outcome for the acute mania example in Figure 3 . Only 4 of a total of 31 loops showed inconsistency, yielding 95% CIs that exclude 0 (that is, the direct estimate of the summary effect differs statistically from the indirect estimate).
Meta-analyses (or, as is often the case, single studies) contributing to inconsistent loops should be scrutinized for outlying studies, and primary data should be checked for errors. If data are shown to be correct after double checking and inconsistency is still evident, researchers should explore other sources of inconsistency. Doing so (through network meta-regression or subgroup analysis) may enhance understanding of how interventions seem to work under different conditions and why certain sources are more reliable than others. In the acute mania example, data extraction and data entry were found to be correct. No important variables could be identified that differed across comparisons in the 4 inconsistent loops, although the numbers of included studies were very small in these loops. Models with and without imposition of the consistency assumption fitted similarly well with the data, which suggested that the more parsimonious consistency model might be preferable (12) .
When inconsistency cannot be explained after considering effect modifiers, researchers may synthesize the data to reflect this additional uncertainty. Models can be applied to relax the consistency assumption by adding an Check the data Studies that stand out in the forest plot are checked for data extraction errors (28, 29) .
Inconsistency in a loop may suggest data errors in extraction or transitivity violations (26) .
Look for data extraction errors in loops that present inconsistency and in comparisons with large heterogeneity. Amend the data and redo the analysis with the correct data set. Try to bypass Empirical evidence shows that some effect measures are associated with larger heterogeneity than others (30, 31) .
Empirical evidence shows that the 3 measures for dichotomous outcomes are similarly prone to inconsistency (26) .
Statistical heterogeneity and inconsistency might change if the measure of treatment effect is changed. Relative and standardized measures (odds ratio, risk ratio, standardized mean difference, and ratio of means) may be more homogeneous than difference measures (mean differences and risk difference). Explore it Study-level variables (ideally prespecified) can be investigated in a subgroup analysis or metaregression (32).
The network may be split into subgroups, or network meta-regression can be used to account for differences across studies and comparisons. The variables, including bias-related characteristics, should ideally be specified in the protocol (18, 19) .
Adjustment for factors that can vary across comparisons may improve the plausibility of the transitivity assumption and reduce heterogeneity. As with simple meta-regression, network meta-regression can have low statistical power and high rates of false-positive results if heterogeneity is ignored and may be prone to ecological bias when aggregated data are used as covariates. Statistical expertise and careful interpretation of the results are required.
Encompass it
Random-effects meta-analysis can be applied (33, 34) .
Models can be applied that relax the consistency assumption (4). These models account for the extra variation in the summary network estimates due to unexplained inconsistency.
Just as random effects are not a remedy for large heterogeneity and should be applied only for moderate amounts of unexplained heterogeneity, inconsistency models should be used to allow for only moderate amounts of unexplained inconsistency. Fitting inconsistency models needs statistical expertise, and their results need to be interpreted with caution.
Resign to it
Investigators may decide not to undertake meta-analysis in the presence of important unexplained heterogeneity.
Investigators may decide not to synthesize the network in the presence of important unexplained inconsistency.
If important statistical heterogeneity or inconsistency remains even after adjustment for possible explanatory variables, researchers might choose not to synthesize the data. This decision should be guided by clinical understanding of the field and careful examination of the consequences for policymakers and patients. extra random effect to each loop (4). Such models have a conceptual analogy to the random-effects model in standard pairwise meta-analysis, which postulates that the true study-specific relative treatment effects are not identical but are similar in that they form a common distribution around the average treatment effect. Random effects in pairwise meta-analysis incorporate the additional uncertainty associated with heterogeneity. Similarly, a model with random inconsistency effects assumes that the different source-specific effects (direct and various indirect effects via different routes) are not identical but are similar. However, incorporation is not the same as adjustment. Because random effects should be applied only for a moderate amount of unexplained heterogeneity, inconsistency models would be most appropriately used to encompass a moderate amount of unexplained inconsistency and not viewed as an attempt to adjust for it.
Research and Reporting Methods

WHEN CAN WE RELY ON DIRECT, INDIRECT, OR MIXED EVIDENCE?
The issue of choosing among direct, indirect, and mixed evidence may arise, particularly when important inconsistency is identified. Arguments exist for giving priority to direct evidence because it does not rely on the transitivity assumption. For example, if the transitivity assumption does not hold, then conclusions from direct evidence may relate to different populations or contexts, but each can be valid for the contexts in which the trials were done. If transitivity seems plausible, then mixed evidence may be preferable to direct evidence because of the ability to compare treatments that have not been directly compared in any trial and the improvement in precision for the estimated effect sizes. In some situations, indirect evidence may be more reliable than direct or mixed evidence. This may be the case if all of the direct evidence (for example, novel treatments compared with placebo) is subject to similar types of bias (for example, in favor of the novel treatment), such that these can theoretically be cancelled out when indirect comparisons are made (35) . More important, if there are inconsistencies between direct and indirect evidence, one should not choose between sources of evidence but should instead investigate the sources of inconsistency to explain the differences. If a large amount of inconsistency remains unexplained after considering effect modifiers, researchers may decide not to synthesize the available evidence in a network meta-analysis. This decision should be acknowledged and discussed in the report, Each diamond represents the difference between direct and indirect estimates in terms of standardized mean difference for efficacy; the corresponding horizontal line represents its 95% CI. For loops with no inconsistency (in green), this difference is 0 and the CI has 1 negative and 1 positive limit (across 0). If the limits of the CI are greater or less than 0, there is statistically significant inconsistency (in red). Data from reference 11.
and other possible reasons for inconsistency should be thoroughly investigated.
HOW MIGHT INCONSISTENCY IN NETWORK META-ANALYSIS BE EXPLAINED?
Meta-regression can be used to explore inconsistency due to differences across studies and comparisons (19, 20) . It can be used to examine causes of inconsistency (typically by using covariates at the comparison level) or to adjust for different distributions of effect modifiers across studies making different comparisons. For example, interventions that are given to more severely ill patients probably will be favored over placebo. Adjustment for factors that vary across comparisons may improve the plausibility of the transitivity assumption while reducing heterogeneity. Through network meta-regression, uncovering the "true" relative effectiveness of each drug is theoretically possible.
As with simple meta-regression, network metaregression can have low statistical power and high rates of false-positive results if heterogeneity is ignored. Specific statistical expertise and careful interpretation of the results are required (36) . Individual-participant data will often be needed to explore effect modification when participantlevel covariates are of interest.
Inconsistency may be due to bias. For example, it might be difficult to blind participants in trials of interventions with important side effects but straightforward to do so in those without such side effects. Such trial characteristics can be accounted for in a subgroup analysis or through network meta-regression. By combining studies that compare treatments with various comparators, network meta-analysis enables researchers to explore biases that are difficult to assess in head-to-head meta-analysis. For example, if treatment A is always industry-funded when compared with placebo (C), the potential effect of industry funding (sponsorship bias) in AC trials alone is impossible to account for. However, in a network, we might have studies that compare A with C (all sponsored by the manufacturer of treatment A) and those that compare A with other active treatments in which A is not always the sponsored group (for example, if some AB studies are sponsored by the manufacturer of treatment A and others by the manufacturer of treatment B). We can adjust for sponsoring in all comparisons, including the AC comparisons, as long as we can assume that any such bias is similar wherever it exists across all sponsored interventions (37) (38) (39) .
HOW CAN RESULTS FROM NETWORK META-ANALYSIS BE PRESENTED IN A CLINICALLY USEFUL WAY?
Graphical presentation of the evidence network, as seen in Figure 1 , provides an accessible and understandable format for describing the evidence base contributing to a network meta-analysis (16, 40) . By plotting nodes and edges proportional to the amount of information they carry, the graphical presentation conveys how much evidence is available for each direct comparison and which contributes most to the network meta-analysis.
It is useful to report direct estimates and estimates from the network meta-analysis (which may be mixed or based on indirect evidence alone), all with their corresponding uncertainty intervals. This provides a complete and transparent picture of the available evidence and helps to highlight where possible disagreements may occur. Most published network meta-analyses use a table or graph to report this information. Effect sizes are often presented as a league table or in a forest plot against a common comparator (11) .
Network meta-analyses also enable estimation of the probability that each intervention is the best for each outcome. Probabilities for each treatment taking each possible rank can be plotted in absolute and cumulative rankograms (37, (41) (42) (43) or presented in a table (44) (Appendix Figures 2 and 3 , available at www.annals.org). It is important to look at the probabilities rather than the naive rankings before drawing conclusions because the latter may be misleading. Ranking measures and probabilities are straightforward to understand and a convenient way to present network results because clinicians usually want to know the preferential order of treatments that could be prescribed to an average patient. However, clinicians should always be interested in the effect sizes and the rankings because a good rank does not necessarily imply a large or clinically important effect size.
HOW MANY STUDIES ARE NEEDED TO CONDUCT A NETWORK META-ANALYSIS, AND WHICH IS THE BEST STATISTICAL APPROACH TO USE?
In general, the more treatments and studies included in a network, the more clinically informative the network meta-analysis. Large data sets might, however, increase the variability across comparisons and studies and render the transitivity assumption difficult to defend. Technically, each treatment of interest must be represented by at least 1 study and the network needs to be connected. A large network informed by few studies often yields imprecise estimates.
Network meta-analysis can be done using frequentist or Bayesian statistical techniques, although to date most have used the latter. Bayesian applications are typically done in WinBUGS (Medical Research Council's Biostatistics Unit, Cambridge, United Kingdom) (45) , and codes for various types of data are available online (for example, nicedsu.org.uk, www.mtm.uoi.gr, and www.bristol.ac.uk /social-community-medicine/projects/mpes/).
CONCLUSION
We have outlined many conceptual and technical issues in network meta-analysis to help clinicians familiarize themselves with this increasingly important method (Appendix Table 2 ). As for all systematic reviews, network meta-analysis should be based on detailed protocols, ideally registered prospectively (46, 47). A detailed protocol protects against data-driven decisions, such as selective use of indirect evidence. It should describe the strategy that the researchers plan to follow to evaluate transitivity and consistency, list factors that could introduce heterogeneity and inconsistency, detail the conditions under which a network meta-analysis will be used to synthesize the results, and specify how inconsistency will be addressed if found. Online registries or databases of systematic reviews (such as PROSPERO [www.crd.york.ac.uk/prospero] or The Cochrane Library [www.thecochranelibrary.com]) provide natural destinations for publication of these details.
A comprehensive search of the literature, careful assessment of the body of evidence with respect to the plausibility of the transitivity assumption, and thoughtful discussion of the potential impact of trial-specific biases on the effect estimates can maximize transparency of a network meta-analysis and avoid errors in its interpretation (15) . The methods for network meta-analysis will no doubt continue to develop and will be informed by the experience gained from increased use. Such applications, with accompanying critical evaluation of the methods by collaborative groups of epidemiologists, statisticians, clinicians, and policymakers, will establish and maintain standards for reporting and interpreting network meta-analysis. 
Rank of Drug D
Network meta-analyses enable estimation of the probability that each intervention is the best for each outcome. Probabilities for each treatment taking each possible rank can be plotted in absolute rankograms or cumulative rankograms. These absolute rankograms (modified from reference 41) rank for response rate (efficacy is the solid red line) and withdrawal rate (acceptability is the dotted blue line). Ranking indicates the probability to be the best treatment, the second best, the third best, and so on, among the group of 12 antidepressants under investigation. For example, drug A has a higher probability to be among the worst antidepressants in terms of efficacy and acceptability, although drug B is good. Network meta-analyses enable estimation of the probability that each intervention is the best for each outcome. Probabilities for each treatment taking each possible rank can be plotted in absolute rankograms or cumulative rankograms. These cumulative rankograms (modified from reference 41) show the distribution of the probabilities of each treatment to be ranked at each of the possible 14 positions within the group of antimanic drugs under investigation. The larger the surface below the cumulative ranking curve (usually called SUCRA), the more probable the drug will be among the lowest ranks (that is, the more effective or acceptable the treatment). For example, drugs A and B have a higher probability to be among the best antimanic drugs (drug B is better than drug A), although drug C is likely among the worst. The SUCRA can be quantified and reported in tables to show its mean values together with the 95% CIs. 
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